PULMICORT (budesonide) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. First approved in 1997.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
PULMICORT (budesonide) is an inhaled corticosteroid that works as a glucocorticoid receptor agonist to reduce airway inflammation. It is used primarily for asthma and COPD maintenance therapy via inhalation powder. The drug targets patients requiring long-term anti-inflammatory control to reduce exacerbations and improve lung function.
As LOE approaches with modest Part D spending ($222K in 2023), the brand team is likely consolidating resources and shifting focus toward life-cycle extension or transition planning.
Corticosteroid Hormone Receptor Agonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
Worked on PULMICORT at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PULMICORT offers exposure to mature-market strategy, managed care negotiations, and life-cycle optimization in a competitive commodity space. Career progression is likely tied to defending market share, extending exclusivity through formulation or indication work, or managing transition to generic/authorized generic models.